Aliskiren/hydrochlorothiazide

Drug Profile

Aliskiren/hydrochlorothiazide

Alternative Names: Hydrochlorothiazide/aliskiren; Rasilez HCT; Riprazo HCT®; Sprimeo HCT®; Tekturna HCT

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives; Benzothiadiazines; Fumarates; Small molecules
  • Mechanism of Action Diuretics; Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 16 Mar 2017 PDL Biopharma has patent protection for Aliskiren/hydrochlorothiazide in USA (PDL Biopharma Annual Reporl,
  • 06 Jul 2016 Noden Pharma completes acquisition of aliskiren/hydrochlorothiazide from Novartis
  • 24 May 2016 Noden Pharma acquires aliskiren/hydrochlorothiazide from Novartis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top